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Summary
The evolutionarily conserved phosphoinositide 3-kinase (PI3K) signaling pathway mediates both the metabolic effects of
insulin and the growth-promoting effects of insulin-like growth factor-1 (IGF-1). We have generated mice deficient in both
the p85a/p55a/p50a and the p85b regulatory subunits of class IA PI3K in skeletal muscles. PI3K signaling in the muscle of
these animals is severely impaired, leading to a significant reduction inmuscle weight and fiber size. Thesemice also exhibit
muscle insulin resistance andwhole-body glucose intolerance. Despite their ability tomaintain normal fasting and fed blood
glucose levels, thesemice show increased body fat content and elevated serum free fatty acid and triglyceride levels. These
results demonstrate that in vivo p85 is a critical mediator of class IA PI3K signaling in the regulation of muscle growth and
metabolism. Our finding also indicates that compromised muscle PI3K signaling could contribute to symptoms of hyper-
lipidemia associated with human type 2 diabetes.Introduction
Class IA phosphoinositide 3-kinases (PI3Ks) are a family of lipid
kinases that phosphorylates the 30-OH position on the inositol
ring of phosphatidylinositol-4,5-bisphosphate (PIP2) to generate
the lipid second messenger phosphatidylinositol-3,4,5-tri-
sphosphate (PIP3) (Cantley, 2002). In mammalian cells class IA
PI3Ks regulate cell metabolism and cell growth downstream of
the insulin and the insulin-like growth factor-1 (IGF-1) receptors,
respectively (LeRoith et al., 1995; Saltiel and Kahn, 2001). Acti-
vation of these receptors leads to tyrosine phosphorylation of
the insulin receptor substrate (IRS) family of adaptor molecules,
particularly IRS-1 and IRS-2. IRS proteins in turn recruit and
activate class IA PI3K (Virkamaki et al., 1999). The lipid phospha-
tase PTEN dephosphorylates the 30 position on PIP3 to regener-
ate PIP2 and therefore terminates PI3K signaling (Cantley, 2002).
This insulin-PI3K signaling pathway is highly conserved
throughout evolution and critically regulates of growth and
metabolism in C. elegans and D. melanogaster (Guarente and
Kenyon, 2000).
Class IA PI3K is a heterodimer consisting of a p85 regulatory
subunit and a p110 catalytic subunit. The p85 regulatory subunit
is essential for the stability of the p110 catalytic subunit (Yu et al.,
1998b; Brachmann et al., 2005). In addition, p85 also mediates
the activation and membrane recruitment of the p85-p110
heterodimer through the binding of its two Src-homology 2
(SH2) domains to phosphotyrosine residues on activated growth
factor receptors or their adaptor molecules such as IRS-1 and
IRS-2 (Yu et al., 1998a). In mammals, there exist multiple iso-
forms of p85 and p110. The major p85 isoforms p85a, p55a,
and p50a are encoded by a single gene pik3r1 through alterna-
tive transcription initiation sites. Two other minor isoforms, p85bCELL METABOLISM 3, 355–366, MAY 2006 ª2006 ELSEVIER INC. Dand p55g, are encoded by the genes pik3r2 and pik3r3, respec-
tively. The p85a/p55a/p50a and p85b isoforms are expressed
ubiquitously whereas p55g is enriched in the brain and the tes-
tis. Three genes, pik3ca, pik3cb, and pik3cd, encode the three
class IA PI3K catalytic subunit isoforms, p110a, p110b, and
p110d, respectively (Fruman et al., 1998).
A major downstream effector of PI3K signaling is the protein
serine/threonine kinase Akt (also known as protein kinase B or
PKB). Upon membrane recruitment by PIP3, Akt becomes acti-
vated through phosphorylation at Thr-308 in its catalytic loop by
the kinase PDK1 (Mora et al., 2004). Additional phosphorylation
at Ser-473 of Akt leads to its full activation (Bayascas and Alessi,
2005). Akt regulates cell growth and metabolism through the
phosphorylation of a number of target molecules. Akt phosphor-
ylates and inactivates tuberin (TSC2), a component of the TSC1/
TSC2 tuberous sclerosis protein complex. This relieves the
inhibitory effect the TSC1/TSC2 complex exerts on the mamma-
lian target of rapamycin (mTOR), thus allowing mTOR to pro-
mote protein synthesis and cell growth (Richardson et al.,
2004). Akt also phosphorylates and inactivates the forkhead
(FOXO) family of transcription factors that regulate the expres-
sion of a wide range of metabolic, survival and cell cycle genes
(Barthel et al., 2005; Burgering and Medema, 2003). In insulin
responsive tissues such as muscle and fat, Akt promotes the
membrane translocation of the glucose transporter GLUT4
and thus increase cellular glucose uptake (Thong et al., 2005;
Virkamaki et al., 1999). In addition, Akt promotes glycogen
synthesis by phosphorylating and thus inactivating glycogen
synthase kinase 3 (GSK3), an inhibitory kinase for glycogen syn-
thase (Cohen and Frame, 2001).
Muscle atrophy is often associated with diseased states such
as diabetes and cancer. In vitro studies have implicated theOI 10.1016/j.cmet.2006.04.003 355
A R T I C L EIGF-1/PI3K signaling pathway in the regulation of myocyte
growth (Rommel et al., 2001). Consistent with this, hyperactiva-
tion of Akt leads to muscle hypertrophy in vivo (Lai et al., 2004).
At the molecular level, myocyte growth is thought to be pro-
moted by Akt signaling through mTOR and GSK3 (Bodine
et al., 2001; Rommel et al., 2001). In addition, Akt protects
against muscle atrophy through its phosphorylation of the fork-
head transcription factors. This inhibits forkhead-mediated tran-
scription of atrogin-1 (also known as MAFbx) and MuRF1, two
E3 ubiquitin ligases that promote muscle protein degradation
(Sandri et al., 2004; Stitt et al., 2004).
Muscle insulin resistance has been implicated as a major con-
tributor toward human type 2 diabetes (Shulman, 2004). Dele-
tion of the insulin receptor in the muscle leads to muscle insulin
resistance (Bruning et al., 1998), whereas deletion of PTEN in the
muscle enhances insulin sensitivity and protects against diet-
induced hyperglycemia (Wijesekara et al., 2005). PI3K/Akt sig-
naling downstream of the insulin receptor has been implicated
as a critical mediator of glucose uptake and glycogen synthesis
in the muscle (Saltiel and Kahn, 2001).
Previously, we and others have generated mice lacking vari-
ous class IA PI3K subunits in order to understand their in vivo
roles in growth and metabolism. Germline deletion of the
pik3r1 gene (i.e., deletion of all three isoforms p85a, p55a, and
p50a) results in perinatal lethality, although surviving mice sur-
prisingly show improved insulin sensitivity (Fruman et al.,
2000). Similarly, mice heterozygous for the pik3r1 gene, or
mice lacking either p85a alone, p55a and p50a alone, or p85b
all display improved PI3K signaling downstream of the insulin re-
ceptor (Chen et al., 2004; Terauchi et al., 1999; Ueki et al.,
2002b; Mauvais-Jarvis et al., 2002). Subsequent studies re-
vealed that under normal circumstances p85 is stoichiometri-
cally in excess of p110 and monomeric p85 can inhibit PI3K sig-
naling by sequestering tyrosine phosphorylated IRS-1 (Ueki
et al., 2002a; Luo et al., 2005a). A partial reduction in total p85
levels therefore increases the ratio of p85-p110 heterodimer to
p85 monomer, despite the overall reduction in total class IA
PI3K activity. This in turn allows improved PI3K signaling down-
stream of the insulin receptor. On the other hand, mouse embry-
onic fibroblasts (MEFs) lacking both pik3r1 and pik3r2 genes
exhibit severely attenuated class IA PI3K signaling, though the
early lethality of pik3r12/2pik3r22/2 mice during embryogenesis
precludes the analysis of p85 function in adult tissues (Brach-
mann et al., 2005).
To better understand the in vivo roles of the p85 regulatory
subunit and to circumvent the lethality phenotype associated
with the pik3r12/2 and the pik3r12/2pik3r22/2 germline knock-
out (KO) mice, we have engineered mice in which the pik3r1
gene can be deleted in a tissue-specific fashion by the Cre-lox
approach (Luo et al., 2005b). By crossing these mice onto the
pik3r22/2 background, we were able to generate mice with
p85a, p55a, p50a, and p85b all deleted in the tissue of interest.
Here, we show that mice lacking both pik3r1 and pik3r2 in skel-
etal muscles (hereafter referred to as pik3r1 mKO pik3r22/2
mice) exhibit severely impaired PI3K signaling in skeletal
muscles, thus demonstrating genetically that the p85 regulatory
subunit is essential in mediating the activation of class IA PI3K.
These animals have smaller muscles that are associated with
reduced fiber size. In addition, their skeletal muscles are insu-
lin-resistant and consequently these mice are glucose intoler-
ant. Fasting and fed glucose and insulin levels remain normal,356however, suggesting adequate compensation from other
insulin-sensitive tissues. Interestingly, these animals show
increased adiposity and exhibit symptoms of hyperlipidemia
that is associated with human type 2 diabetes. These results
demonstrate that in vivo class IA PI3K is both an important
regulator of muscle growth and a critical mediator of insulin
signaling in the muscle.
Results
Impaired muscle PI3K signaling in pik3r1 mKO
pik3r22/2 mice
We engineered a conditional allele of the mouse pik3r1 gene
(pik3r1fl) by flanking exon 7 with loxP sites. Cre-mediated dele-
tion of exon 7 introduces a stop codon in the mRNA, thus ablat-
ing the expression of p85a, p55a and p50a proteins (Luo et al.,
2005b). We crossed pik3r1fl/fl mice with mck-cre transgenic
mice that express the Cre recombinase specifically in striated
myocytes (Bruning et al., 1998) and obtained mice with mus-
cle-specific deletion of the pik3r1 gene (hereafter referred to
as pik3r1 mKO). In the skeletal muscles of pik3r1 mKO mice
we observed efficient deletion of p85a, p55a and p50a expres-
sion that is accompanied by a significant reduction in the levels
of p110a protein (Figure 1A). We further crossed pik3r1 mKO
mice with pik3r22/2 mice to generate pik3r1 mKO pik3r22/2
mice that lacked p85a, p55a, p50a and p85b proteins in the
muscle (Figure 1C). The residual p85 proteins in the pik3r1
mKO pik3r22/2 mice might be attributed to other cell types in
the muscle (such as satellite cells, adipocytes and endothelial
cells) or the incomplete deletion of the pik3r1 gene in a small
fraction of myocytes.
The mck-cre transgene expresses in both the skeletal muscle
and the heart. Previously we have characterized the cardiac
phenotype of the pik3r1 mKO pik3r22/2mice and demonstrated
that these animals show reduced heart size and impaired
cardiac hypertrophy (Luo et al., 2005b). In the present study,
we focused on the skeletal muscle phenotype of these animals.
We first investigated PI3K signaling in skeletal muscles of
these animals. Deletion of pik3r1 alone or in combination with
pik3r2 resulted in a severe impairment of PI3K activation down-
stream of the insulin receptor. In both pik3r1 mKO and pik3r1
mKO pik3r22/2 mice, muscle IRS-1 and IRS-2 associated
PI3K activities following insulin stimulation were reduced
approximately 7- and 3- fold, respectively (Figure 1B). Interest-
ingly, Akt activation, as judged by phosphorylation at Thr-308
and Ser-473, was only significantly attenuated in the muscles
of pik3r1 mKO pik3r22/2 mice, but not in that of the pik3r1
mKO mice (Figure 1C). Previous studies using germline KO
mice lacking Akt1 or Akt2 indicate that Akt1 predominately reg-
ulates growth whereas Akt2 predominately regulates glucose
homeostasis (Cho et al., 2001a, 2001b; Tschopp et al., 2005).
We therefore examined the activation of Akt1 and Akt2 sepa-
rately by immunoprecipitation using isoform-specific anti-
bodies. As shown in Figure 1C, similar to total Akt phosphoryla-
tion, we observed severe attenuation inT308 and S473
phosphorylation of both Akt1 and Akt2 in the muscle of pik3r1
mKO pik3r22/2 mice in response to insulin. Thus in vivo class
IA PI3K mediates the activation of both Akt1 and Akt2 by insulin
in the muscle. Downstream of Akt, we found that insulin-
stimulated phosphorylation of GSK3a/b and tuberin by Akt
were significantly impaired in muscles of pik3r1 mKOCELL METABOLISM : MAY 2006
PI 3-kinase regulates muscle growth and metabolismFigure 1. pik3r1 mKO pik3r22/2 mice show severely impaired PI3K signaling in skeletal muscles in response to insulin stimulation
A) Gastrocnemius muscle lysates from mice of the indicated genotypes were probed with anti-p85 and anti-p110a antibodies to assess the deletion efficiency of p85.
B) Mice were stimulated with either saline or 5 U/kg insulin for 5 min and PI3K activities associated with IRS-1 (top) and IRS-2 (bottom) immunoprecipitates from muscle
lysates were measured by in vitro PI3K assay (n = 3, *p < 0.01 compared to pik3r1fl/fl mice of the same treatment group).
C) Mice were stimulated with either saline or 5 U/kg insulin for 5 min, Akt activation and Akt-mediated phosphorylation of downstream substrates in the muscle were
assessed by Western blot using the appropriate phosphospecific antibodies (the total Akt antibody recognizes the unphosphorylated form of Akt better). Representative
blots of 3 independent experiments are shown. All error bars represent standard errors of the mean.pik3r22/2 mice (Figure 1C). GSK3a/b phosphorylation was also
somewhat decreased in the muscle of some pik3r1 mKO mice,
although this result was variable. Otherwise, deletion of pik3r1
alone or pik3r2 alone had little effect on signaling downstream
of Akt. As a control, Erk activation by insulin was unaffected in all
cases. Taken together, these results suggest that in the absence
of p85a isoforms, muscle PI3K signaling is severely compro-
mised though Akt activation is largely unaffected. This could
be due to compensation from the p85b isoform. When both
p85a and p85b isoforms are ablated, however, muscle Akt sig-
naling is severely impaired.
Muscle PI3K signaling downstream of the IGF-1 receptor has
been implicated in the regulation of myocyte growth (Bodine
et al., 2001; Rommel et al., 2001). We therefore investigatedCELL METABOLISM : MAY 2006whether Akt activation downstream of IGF-1 receptor is also
impaired in the muscle of pik3r1 mKO pik3r22/2 mice. Similar
to that observed with insulin stimulation, IGF-1 mediated PI3K
activation is also severely impaired in the muscle of these
animals (Figure 2A). Again both Akt1 and Akt2 activation was
significantly attenuated, resulting in reduced phosphorylation
of downstream targets such as tuberin and GSK3 (Figure 2B).
Reduced muscle weight and myocyte size in pik3r1 mKO
pik3r22/2 mice
As PI3K signaling has been implicated in the regulation of mus-
cle growth and fiber size (Rommel et al., 2001), we investigated
whether the pik3r1 mKO pik3r22/2 mice showed symptoms of
muscle atrophy due to impaired PI3K signaling. Both male and357
A R T I C L Efemale pik3r1 mKO pik3r22/2 mice have normal body weight
(Figure 3A). Although in some study groups we observed a re-
duction in total body weight in some pik3r1 mKO pik3r22/2
Figure 2. pik3r1 mKO pik3r22/2 mice show severely impaired PI3K signaling in
skeletal muscles in response to IGF-1 stimulation
A) Control pik3r1fl/fl and pik3r1 mKO pik3r22/2 mice were stimulated with either
saline or 1mg/kg IGF-1 for 7 min, and PI3K activities associated with IRS-1 (top)
and IRS-2 (bottom) immunoprecipitates from muscle lysates were measured by
in vitro PI3K assay (n = 3, *p < 0.01 compared to pik3r1fl/fl mice of the same treat-
ment group).
B)Mice were stimulated with either saline or 1mg/kg IGF-1 for 7 min, Akt activation
and Akt-mediated phosphorylation of downstream substrates in the muscle were
assessed by Western blot using the appropriate phosphospecific antibodies
(*cross-reacting band). Representative blots of 3 independent experiments are
shown. All error bars represent standard errors of the mean.358mice, the difference did not reach overall statistical significance.
The gastrocnemius muscles of the pik3r1 mKO pik3r22/2 mice,
however, were approximately 30% lighter than control mice
when normalized to body weight (Figure 3B). Thus loss of class
IA PI3K signaling in the muscle leads to a reduction in muscle
weight. We next examined muscles fibers from pik3r1 mKO
pik3r22/2mice. Although histologically these fibers showed nor-
mal structure, they appeared to have smaller cross-sectional
areas (Figure 3C). Indeed, morphormetric analysis of the tibialis
anterior muscle from pik3r1 mKO pik3r22/2 mice revealed an
approximately 40% reduction in both median and mean fiber
size compared to age-matched mice of similar body weight (Fig-
ures 3D and 3E). Thus the reduction in muscle size in pik3r1
mKO pik3r22/2 mice can be attributed to a reduction in fiber
size. Given that Akt mediated tuberin phosphorylation was at-
tenuated in the muscle of pik3r1 mKO pik3r22/2 mice (Figures
1C and 2B), it is likely that impaired mTOR signaling and protein
synthesis is at least in part responsible for the attenuated muscle
growth in these animals. Consistent with this, we observed that
in response to feeding, the muscle of pik3r1 mKO pik3r22/2
mice show attenuated Akt activation as well as phosphorylation
of ribosomal S6 and 4EBP1, two key downstream effectors of
mTOR that controls translation (Figure 3F).
Myocyte size can also be regulated by protein degradation.
Fasting induces the expression of muscle E3-ubiquitin ligase
atrogin-1/MAFbx and MuRF1 in a forkhead-dependent fashion.
This facilitates muscle protein breakdown (Sandri et al., 2004;
Stitt et al., 2004). We investigated whether atrogin-1/MAFbx
and MuRF1 message levels were mis-regulated in pik3r1 mKO
pik3r22/2 mice. Under the fed state, muscle atrogin-1/MAFbx
and MuRF-1 mRNAs were below detection limit by real-time
PCR for both control and pik3r1 mKO pik3r22/2 animals. During
prolonged fasting, however, these mRNAs were markedly upre-
gulated in animals of both genotypes. Unexpectedly, we found
that muscle atrogin-1/MAFbx and MuRF1 mRNA levels were
significantly lower in pik3r1 mKO pik3r22/2 mice compared to
that of control mice (Figure 3G). Thus it is unlikely that the de-
creased muscle size is due to enhanced muscle atrophy in the
pik3r1 mKO pik3r22/2 mice.
The small muscle size in pik3r1 mKO pik3r22/2 mice did not
appear to significantly impair the animal’s ability to perform
chronic exercise. Using citrate synthase (CS) activity as an indi-
cator of the muscle’s response to exercise load, we found that
under sedentary conditions muscle CS activity was only mildly
reduced in the pik3r1 mKO pik3r22/2 mice. When subjected to
aerobic exercise training for 1 month in the form of swimming,
the increase in CS activity in pik3r1 mKO pik3r22/2 mice
(149%) was comparable to that in WT mice (145%) (Figure 3H;
Luo et al., 2005b).
pik3r1 mKO pik3r22/2 mice exhibit muscle insulin
resistance, glucose intolerance, hyperlipidemia
and increased adiposity
Skeletal muscle is a major insulin responsive tissue and a major
site of glucose disposal in vivo. Muscle insulin resistance is a sig-
nificant contributing factor toward human type 2 diabetes (Shul-
man, 2004). We first investigated insulin-stimulated glucose
uptake in isolated soleus muscle (an oxidative muscle that is
insulin responsive) and extensor digitorum longus (EDL) muscle
(a glycolytic muscle that is less insulin responsive) ex vivo.
Soleus muscles from pik3r1 mKO pik3r22/2 mice showedCELL METABOLISM : MAY 2006
PI 3-kinase regulates muscle growth and metabolismmodestly impaired 2-deoxyglucose uptake in response to both
submaximal (0.6mU/ml) and maximal (50mU/ml) doses of insulin
(Figure 4A). EDL muscles were only responsive to maximal insu-
lin, and 2-deoxyglucose uptake in EDL muscles from pik3r1
mKO pik3r22/2 mice was also impaired (Figure 4A). Thus the
loss of muscle PI3K signaling in pik3r1 mKO pik3r22/2 mice
led to muscle insulin resistance, although the effect was not
as severe as might have been expected considering the dra-
matic reduction in muscle Akt signaling (Figure 1). Consistent
with this, we found that pik3r1 mKO pik3r22/2 mice to have
lower muscle glycogen content in the fed state compared to
control animals (Figure 4B).
We investigated the possibility that muscle insulin resistance
was sufficient to perturb whole-body glucose homeostasis in
pik3r1 mKO pik3r22/2 mice. We first assessed whole-body glu-
cose disposal using the glucose tolerance test (GTT). Following
the injection of a bolus dose of glucose, the pik3r1 mKO
pik3r22/2 mice showed both higher peak blood glucose levels
(at 60 min) and more sustained elevation in blood glucose levels
compared to control mice (Figure 4C), indicating these animals
were glucose intolerant. Such glucose intolerance was also ob-
served when animals were placed on a high-fat diet for 12 weeks
(Figure 4C). Despite impaired glucose disposal, insulin release
during GTT, as well as insulin sensitivity during insulin tolerance
tests were normal in pik3r1mKO pik3r22/2mice (Figures 4D and
4E). These mice also had normal fasting and fed blood glucose
and serum insulin levels (Table 1). In addition, high-fat diet did
not make them more insulin resistant than control animals dur-
ing ITT (data not shown). Taken together, these results suggest
that although muscle insulin resistance alone is sufficient to
cause glucose intolerance, it is insufficient to cause hyperglyce-
mia, and other insulin responsive tissues could compensate for
the defect in muscle insulin-sensitivity.
Interestingly, deletion of pik3r1 alone in muscle did not result
in a significant effect on glucose disposal (Figures 4C and 4E).
This is in stark contrast to mice with germline deletion of
pik3r1 where a dramatic increase in insulin-dependent glucose
disposal is observed (Fruman et al., 2000; Ueki et al., 2002b;
Terauchi et al., 1999). These results indicate that tissues other
than muscle are responsible for the enhanced insulin response
in mice lacking p85a.
We next investigated whether adipose tissue, another major
site of glucose disposal, might compensate for the reduction
in muscle insulin resistance in pik3r1 mKO pik3r22/2 mice and
thus maintain whole-body glucose homeostasis. A DEXA scan
analysis of body fat content in age- and weight-matched
animals revealed that pik3r1 mKO pik3r22/2 mice showed an
approximately 30% increase in body fat (Figure 5A). Similarly,
epididymal fat pads from these mice were approximately 70%
heavier than those from control mice when adjusted to body
weight (Figure 5B). The increased adiposity in pik3r1 mKO
pik3r22/2 mice was accompanied by an increase in serum lipid
levels. Fasting serum free fatty acids in pik3r1 mKO pik3r22/2
mice were approximately 30% higher than those from control
mice, whereas fasting and fed serum triglycerides levels in these
animals were over 60% higher than those from control animals
(Figures 5C and 5D, Table 1). Taken together, these results sug-
gest that muscle insulin resistance in pik3r1 mKO pik3r22/2
mice triggers compensatory metabolic changes that lead to in-
creased adiposity and elevated circulating lipid levels, two
symptoms that are also associated with human type 2 diabetes.CELL METABOLISM : MAY 2006Discussion
The evolutionarily conserved PI3K signaling pathway is an im-
portant regulator of growth and metabolism. In the present
study we have shown that the deletion of the p85a/p55a/p50a
and p85b regulatory subunits of class IA PI3K in the muscle
severely impairs PI3K signaling and leads to decreased muscle
size, decreased insulin-stimulated muscle glucose uptake, and
impaired whole-body glucose disposal. These results demon-
strate genetically that p85 is essential for class IA PI3K signaling
in vivo and muscle PI3K signaling critically regulates myocyte
size and muscle metabolism. In addition, we found that loss of
muscle PI3K signaling leads to indirect effects on the adipose
tissue and causes increased adiposity and elevated levels of cir-
culating lipids.
The p85 regulatory subunit of class IA PI3K is essential for the
stability of the p110 catalytic subunit and is required to mediate
the receptor/adaptor recruitment and activation of p110 (Brach-
mann et al., 2005; Yu et al., 1998a, 1998b). Germline knockout
mice lacking various p85 isoforms, however, all exhibited im-
proved PI3K signaling (Chen et al., 2004; Terauchi et al., 1999;
Ueki et al., 2002b; Mauvais-Jarvis et al., 2002). It was sub-
sequently shown that in cells in culture, p85 is often stoichio-
metrically in excess of p110, and in its monomeric form p85
negatively regulate PI3K signaling (Ueki et al., 2002a, 2003). Mo-
nomeric p85 competes with the p85-p110 heterodimer for IRS
binding and drives the formation of large, nonsignaling seques-
tration complexes with IRS-1 in the cytosol (Luo et al., 2005a).
These in vitro studies offer a possible explanation for why a par-
tial loss of p85 in vivo results in increased insulin sensitivity.
The attempt to understand the role of p85 in insulin signaling
in vivo has been precluded by the perinatal lethality associated
with mice with germline deletion of the pik3r1 gene and the em-
bryonic lethality associated with mice doubly null for the pik3r1
and pik3r2 genes (Brachmann et al., 2005; Fruman et al., 2000).
In addition, the crosstalk between different insulin-responsive
tissues in vivo makes it difficult to elucidate the tissue-specific
roles of p85 and PI3K in the regulation of metabolism. To over-
come these drawbacks, we have generated a conditional
(floxed) pik3r1 allele that allows tissue-specific deletion of this
gene using the Cre-lox approach (Luo et al., 2005b).
When we crossed pik3r1fl/fl mice with mck-cre mice, we ob-
served efficient deletion of p85a, p55a, and p50a, accompanied
by a significant reduction in p110a level (Figure 1A). Conse-
quently, muscle PI3K activation is severely impaired (Figure 1B).
This provides direct evidence that p85 is essential for both the
stability and activation of p110 in vivo. The severe impairment
in muscle PI3K signaling in pik3r1 mKO mice, however, did not
translate into severely impaired Akt signaling downstream
(Figure 1C). This suggests that p85b was able to compensate
for the loss of all p85a isoforms in the muscle. The discordance
between the amount of PI3K bound to IRS proteins and the
magnitude of Akt activation observed in the pik3r1 mKO mice
versus pik3r1 mKO pik3r22/2 mice is consistent with the idea
that only a small fraction of the PI3K bound to IRS-1 is utilized
to generate the PIP3 required for Akt activation, as argued in
the IRS-1 sequestration model (Luo et al., 2005a). Consistent
with the relatively normal activation of Akt in the pik3r1 mKO
mice, myocyte size and muscle metabolism both appeared nor-
mal in these mice. The normal Akt activation in the muscle of
pik3r1 mKO mice also mirrored that observed in muscle from359
A R T I C L EFigure 3. pik3r1 mKO pik3r22/2 mice have reduced muscle weight and myocyte size
A) Body weight of 8 week-old mice.
B) Gastrocnemius muscle to body weight ratio of age-matched male mice (n = 6, *p < 0.01 compared to pik3r1fl/fl mice). Similar results were obtained for female mice (data
not shown).
C) Representative cross-section of tibialis anterior (TA) muscle with H&E stain.
D) Distribution of TA muscle myocyte cross-section area in age- and body-weight-matched control and pik3r1 mKO pik3r22/2mice (n = 3, *p < 0.01 compared to the num-
ber of myocytes in the same size range in pik3r1fl/fl mice).
E) Mean TA muscle myocyte cross-section area as shown in (D) (n = 3, *p < 0.01 compared to pik3r1fl/fl mice).360 CELL METABOLISM : MAY 2006
PI 3-kinase regulates muscle growth and metabolismthe pik3r1 germline knockout mice (Fruman et al., 2000). The
pik3r1 mKO mice exhibited normal glucose tolerance during
GTT and normal fasting and fed blood glucose levels. This indi-
cates that the hypoglycemic and insulin hypersensitive pheno-
type of the germline pik3r1 knockout mice cannot be attributed
to the loss of pik3r1 in the muscle (see below).
To achieve the complete ablation of all p85 regulatory sub-
units in the muscle, we further crossed pik3r1 mKO mice with
pik3r22/2 mice. Both PI3K activation and Akt signaling were se-
verely impaired in the muscles of pik3r1 mKO pik3r22/2 mice,
resulting in growth and metabolic defects. Some residual
amount of p85 proteins and class IA PI3K activity remained in
the muscles of pik3r1 mKO pik3r22/2 mice. This could be due
to incomplete deletion of the pik3r1 gene in a few myocytes,
or contribution from nonmyocyte cells in the muscle such as sat-
ellite cells, endothelium and adipocytes. Dramatic upregulation
of p55g has been observed in pik3r12/2pik3r22/2MEFs in com-
pensation for the loss of all other p85 isoforms (Brachmann
et al., 2005). We did not detect significant levels of p55g proteins
in muscles from either control or pik3r1 mKO pik3r22/2 mice
(data not shown). Thus it is unlikely that p55g is dramatically up-
regulated in the muscle of pik3r1 mKO pik3r22/2 mice, although
our inability to detect p55g in the muscle could also be attributed
toward the lack of antibody sensitivity.
Genetic studies in mice indicate that the IGF-1/PI3K signaling
pathway regulates growth and development. Germline deletion
of the IGF-1 receptor results in severe growth retardation (Liu
et al., 1993), whereas cardiac-specific expression of IGF-1 re-
ceptor results in enlarged hearts (McMullen et al., 2004). We
have previously shown that pik3r1 mKO pik3r22/2 mice have
reduced heart size (Luo et al., 2005b), whereas the cardiac over-
expression of a constitutively active form of p110 increases
heart size (Shioi et al., 2000). Genetic manipulation of PTEN
and Akt also leads to development and growth phenotypes
(Backman et al., 2001; Chen et al., 2001; Kwon et al., 2001;
Cho et al., 2001b; Groszer et al., 2001). In the present study
we show that the loss of PI3K signaling in the muscle results
in reduced muscle weight and myocyte size (Figures 3B–3E),
thus demonstrating a key role of PI3K in the regulation of muscle
growth. Interestingly, class IA PI3K appears to exclusively regu-
late muscle growth and fiber size, as fiber structure and the abil-
ity of the muscle to respond to increased exercise load appear
minimally impacted by the loss of PI3K signaling (Figures 3C
and 3H). It remained to be determined, however, whether loss
of PI3K signaling also negatively impact muscle contractility.
The mTOR pathway that controls protein synthesis and cell
growth is likely to contribute toward the small muscle phenotype
observed in pik3r1 mKO pik3r22/2 mice (Rommel et al., 2001).
Both insulin and IGF-1 stimulated tuberin phosphorylation by
Akt in the muscle was impaired in these mice (Figures 1C and
2B). In addition, muscle Akt, S6 and 4EBP1 phosphorylation
in response to feeding was also diminished in pik3r1 mKO
pik3r22/2mice (Figure 3F). Thus a reduction in protein synthesis
could, at least in part, account for the reduction in muscle size.
Protein degradation through forkhead-mediated expression ofCELL METABOLISM : MAY 2006E3-ubiquitin ligases atrogin-1/MAFbx and MuRF1 have been
implicated in the regulation of muscle atrophy (Sandri et al.,
2004; Stitt et al., 2004). To our surprise, albeit still strongly in-
duced by fasting, the muscle mRNA levels of atrogin-1/MAFbx
and MuRF1 in fasting pik3r1 mKO pik3r22/2 mice were actually
lower than that of control mice (Figure 3F). The mechanisms
behind such attenuation are unclear, although there might be
several potential explanations. It is possible that normally skele-
tal muscle serves as a source of amino acids during prolonged
fast. In the pik3r1 mKO pik3r22/2 mice, however, the loss of
PI3K signaling and reduction in muscle mass may trigger a neg-
ative feedback loop that attenuates muscle protein mobilization
in the fasting state and prevents excessive muscle loss. In addi-
tion, the increased body fat content in the pik3r1 mKO pik3r22/2
mice, together with an elevation in serum lipid and fasting leptin
levels (Figure 5 and Table 1) might also signal to prevent muscle
protein breakdown.
Muscle insulin resistance is a major contributor to human type
2 diabetes (Shulman, 2004). Deletion of PTEN in the muscle
leads to enhanced insulin sensitivity and protection from diet-
induced insulin resistance (Wijesekara et al., 2005). Muscle insu-
lin sensitivity and global glucose tolerance of pik3r1 mKO mice
appeared normal (Figure 4 and data not shown), suggesting
that the hypoglycemia and insulin hypersensitivity phenotype
seen in the germline pik3r12/2 mice cannot be attributed to
the muscle. In a parallel study, we and collaborators have ob-
served that liver-specific pik3r1 deletion recapitulates the im-
proved insulin-dependent serum glucose regulation observed
in germline pik3r1 deletion (C. Taniguchi, J.L., L.C.C., C.R.
Kahn, et al., submitted).
Muscles from pik3r1 mKO pik3r22/2 mice show reduced glu-
cose transport in response to insulin, this in turn leads to re-
duced muscle glycogen content in the fed state and modest
but significant glucose intolerance during GTT (Figure 3). Such
glucose intolerance might also be partially attributable to the
elevated body fat content in these mice. Nevertheless, these an-
imals were able to maintain normal fasting and fed glucose and
insulin levels (Table 1). This suggests muscle insulin resistance
alone, at least in mice, is insufficient to cause diabetes. Our find-
ings largely recapitulate the phenotypes of muscle-specific in-
sulin receptor knockout (MIRKO) mice (Bruning et al., 1998;
Kim et al., 2000). Thus in muscle PI3K is likely to mediate most
(if not all) of the metabolic effect of insulin. Mice with muscle-
specific GLUT4 deletion exhibit more severe perturbation in glu-
cose homeostasis than both the pik3r1mKOpik3r22/2mice and
the MIRKO mice (Zisman et al., 2000). This difference could, at
least in part, be attributed to the loss of basal glucose transport
in the muscle GLUT4 KO mice that was not observed in the latter
two mouse models.
Interestingly, muscle insulin resistance in pik3r1 mKO
pik3r22/2 mice leads to altered lipid metabolism, similar to
that observed in the MIRKO mice. We observed elevated levels
of circulating fatty acids and triglycerides in these animals that
were associated with significantly increased body fat content
(Figure 5). The increase in fat mass appeared to compensateF) Gastrocnemius muscle lysates from fasting and fed mice were probed for Akt, S6 and 4EBP1 phosphorylation to examine feeding-induced activation of the Akt/mTOR
pathway.
G) Muscle atrogin-1/MAFbx and MuRF1 mRNA levels in fasting mice as measured by real-time RT-PCR (n = 3, *p < 0.05 compared to pik3r1fl/fl mice; ND, not detectable).
H) Muscle citrate synthase activity in sedentary mice and mice that were subjected to swim exercise for 1 month. The percentage change in exercise-induced elevation
from basal level of the same genotype was also shown (n = 6). All error bars represent standard errors of the mean.361
A R T I C L EFigure 4. pik3r1 mKO pik3r22/2 mice exhibit muscle insulin resistance and glucose intolerance
A) Insulin-stimulated 2-deoxyglucose (2DG) uptake in isolated soleus and EDL muscle (n = 5–6, #p < 0.06 and *p < 0.01 compared to pik3r1fl/fl mice of the same treatment
group).
B) Muscle glycogen content in fast and fed mice (n = 3, #p< 0.08 compared to pik3r1fl/fl animals of the same group).
C) Glucose tolerance test of 5-month-old males on regular-chow or high-fat (HF) diet (n = 6–8, *p < 0.05 compared to pik3r1fl/fl mice at the same time point).
D) Serum insulin level of 5-month-old males on regular chow diet during DTT as shown in C (n = 6).
E) Insulin tolerance test of 5-month-old males on regular chow diet (n = 6–8). All error bars represent standard errors of the mean.362 CELL METABOLISM : MAY 2006
PI 3-kinase regulates muscle growth and metabolismTable 1. Metabolic parameters of mice in this study
Genotype
Glucose (mg/dL) Insulin (ng/ml) Leptin (ng/ml) FFAs (mEq/L) TG (mg/ml)
fast fed fast fed fast fed fast fed fast fed
pik3r1fl/fl 53 6 5 122 6 6 0.38 6 0.06 1.28 6 0.23 2.2 6 0.7 12.5 6 1.4 1.24 6 0.09 1.10 6 0.10 2.32 6 0.48 3.10 6 0.39
pik3r1 mKO 49 6 2 124 6 11 0.23 6 0.03 1.19 6 0.21 2.9 6 1.1 11.9 6 2.2 1.67 6 0.24 0.86 6 0.14 3.60 6 0.79 3.70 6 0.44
pik3r1fl/fl pik3r2-l- 51 6 3 135 6 9 0.35 6 0.04 0.98 6 0.20 1.4 6 0.7 9.4 6 1.6 1.36 6 0.04 0.97 6 0.15 2.81 6 0.27 3.49 6 0.64
pik3r1 mKO pik3r2-l- 41 6 2 135 6 7 0.45 6 0.09 1.20 6 0.22 5.0 6 1.0* 13.8 6 2.7 1.63 6 0.15* 1.02 6 0.10 3.73 6 0.55 5.22 6 0.59*
n = 6–8, *p < 0.05 compared to pik3r1fl/fl mice of the same group, errors represent standard errors of the mean. FFAs, free fatty acids; TG, triglycerides.for the reduction in muscle mass in pik3r1 mKO pik3r22/2 mice,
thus we did not observe an overall change in body weight. This
metabolic shift could be explained by the conversion of glucose
to lipids in these animals: the reduced muscle glucose disposal
causes elevated lipid synthesis by the liver and increased glu-
cose uptake in adipocytes, thus leading to increased fat storage
(Kim et al., 2000). These findings highlight the crosstalk between
different insulin-responsive tissues in vivo in the coordinated
regulation of glucose homeostasis. The hyperlipidemia and
adiposity phenotype of pik3r1 mKO pik3r22/2 mice resembles
similar symptoms associated with human type 2 diabetes, indi-
cating muscle insulin resistance is at least partially responsible
for the perturbation in lipid metabolism in type 2 diabetes.
Germline knockout mice lacking the insulin receptor exhibit
mild growth retardation but severe metabolic defects (Accili
et al., 1996; Joshi et al., 1996). In contrast, mice lacking the
IGF-1 receptor exhibit severe growth retardation (Liu et al.,CELL METABOLISM : MAY 20061993). These and other studies indicate that in mammals insulin
primarily regulates metabolism where as IGF-1 primarily regu-
lates growth and development. A parallel has been drawn with
Akt1 and Akt2: Akt1 KO mice show growth retardation without
significant alterations in insulin sensitivity (Chen et al., 2001;
Cho et al., 2001b), whereas mice lacking Akt2 show glucose in-
tolerance and insulin resistance (Cho et al., 2001a). The pheno-
types of the pik3r1mKO pik3r22/2mice recapitulate both that of
the insulin and IGF-1 KO mice and that of the Akt1 and Akt2 KO
mice. Thus in the muscle of these mice both Akt1 and Akt2 ac-
tivation are severely impaired in response to either insulin or
IGF-1 stimulation. As a result, the muscle of these animals is
both small and insulin resistant. Our findings therefore indicate
that in the muscle class IA PI3K is a critical activator of both
Akt1 and Akt2 downstream of insulin and IGF-1 signaling. This
raises the question of how insulin and IGF-1, as well as Akt1
and Akt2, regulate different aspects of muscle physiology whileFigure 5. pik3r1 mKO pik3r22/2 mice have increase
body fat content and elevated circulating lipid levels
A) Body fat content as measured by DEXA scan in
5-month old males on regular chow diet (n = 6, *p <
0.05 compared to pik3r1fl/fl mice).
B) Epididymal fat pad to body weight ratio in
5-month-old males on regular chow diet (n = 6,
*p < 0.05 compared to pik3r1fl/fl mice).
C) Fasting serum free fatty acids (FFAs) levels in
5-month-old males on regular chow diet (n = 6,
*p < 0.05 compared to pik3r1fl/fl mice of the same
group).
D) Fasting and fed serum triglycerides levels in
5-month-old males on regular chow diet (n = 6,
*p < 0.05 compared to pik3r1fl/fl mice of the same
group). All error bars represent standard errors of
the mean.363
A R T I C L Eutilizing class IA PI3Ks as a common signaling node (Taniguchi
et al., 2006). It is possible that under physiological conditions, in-
sulin and IGF-1 might elicit different magnitude and duration of
PI3K signaling that preferentially activate different downstream
targets (e.g., Akt1 vs. Akt2). In addition, insulin and IGF-1 recep-
tors might also differentially activate other signaling pathways
that corroborate with PI3K-Akt to determine signaling outcome.
In conclusion, our current work demonstrate that class IA PI3K
signaling is a critical regulator of both muscle size and muscle
insulin sensitivity in vivo. These findings have broad implication
in the understanding of growth and metabolic regulation. In
addition, our study indicates that attenuated muscle PI3K
signaling could be an important pathological mechanism that
underlies type 2 diabetes.
Experimental procedures
The pik3r1fl/fl mice, pik3r22/2 and mck-cre mice have all been described pre-
viously (Bruning et al., 1998; Ueki et al., 2002b; Luo et al., 2005b). All mice
were maintained on a 129Sv-C57BL/6-FVB mixed background. Animal
care and experimentations were approved by the Institutional Animal Care
and Use Committees of Beth Israel Deaconess Medical Center and Harvard
Medical School.
Glucose tolerance test (GTT) and insulin tolerance test (ITT) were per-
formed as described previously (Ueki et al., 2002b). For GTT, mice were
fasted overnight prior to intraperitoneal injection with glucose solution
(2 mg/kg). For ITT mice were fasted for 4 hr prior to intraperitoneal injection
with insulin solution (1 U/kg). Blood glucose was monitored using a glucom-
eter (Bayer). For high-fat diet treatment, mice were place on a fat-adjusted
diet (50% calories from fat) for 12 weeks. For aerobic exercise training,
mice were subjected to 2 sessions of 90 min swim training daily for 1 month
as described previously (McMullen et al., 2003).
Isolated muscle glucose transport was assayed as described previously
(Bruning et al., 1998). In brief, isolated soleus or EDL muscles from mice
that were fasted overnight were preincubated in gassed (95% O2, 5% CO2)
Krebs-Ringer-Bicarbonate (KRB) buffer (117 mM NaCl, 4.7 mM KCl,
2.5 mM CaCl2, 1.2 mM KH2PO4, 1.2mM MgSO4, 24.6 mM NaHCO3) with
2 mM pyruvate containing 0, 0.6 mU/ml or 50 mU/ml insulin at 30ºC for
40 min. Transport was measured in KRB containing 1mM 2-deoxy-D-
[1,2-3H]-glucose and 7mM D-[14C]-mannitol at 37ºC for 10 min. Muscle gly-
cogen level was measured as described previously (Musi et al., 2005).
Whole-body fat content measurement was carried out in anesthetized
mice using a DEXA-scan X-ray imaging station according to the manufac-
turer’s instructions (GE healthcare). Myocyte cross-section area was quanti-
fied using Image-J software (N.I.H.). At least 100 myocytes were measure per
animal. Serum insulin and leptin levels were measured by ELISA according to
manufacturer’s instructions (Crystal Chem Inc.). Serum free fatty acids and
triglycerides were measured by enzymatic reactions according to manufac-
turer’s instructions (Sigma Aldrich). Muscle citrate synthase activity was
measured by enzymatic method as described previously (McMullen et al.,
2003).
Insulin stimulation in vivo and muscle lysate preparation was carried out as
described previously (Taniguchi et al., 2005; Ueki et al., 2002b). In brief, mice
were fasted overnight and deep anesthetized. Insulin (5 U/kg) was injected
through the inferior vena cava, 5 min later the animals were sacrificed and
muscle samples were collected. IGF-1 injection (1mg/kg) was performed
similarly and muscle samples were collected 7 min following injection. Mus-
cle lysates were prepared by homogenizing muscle samples in lysis buffer
(25 mM Tris-HCl [pH 7.4], 10 mM EDTA, 10 mM EGTA, 100 mM NaF,
50 mM NaPPi, 1% NP-40, 10 mM Na3VO4, 1 mM dithiothreitol, 2 mM phenyl-
methylsulfonyl fluoride, 8 g/ml leupeptin, 8 g/ml aprotinin, and 8 g/ml pepsta-
tin) followed by centrifugation at 150,000 3 g for 20 min.
Antibody against p85 (which reacts strongly with p85a and weakly with
p85b), antibody against phosphotyrosine (4G10) and antibodies against
IRS-1 and IRS-2 were described previously (Ueki et al., 2002b; Fruman
et al., 2000). Antibody against p110a was from BD Biosciences. Antibody
against the insulin receptor b-subunit, antibody against the IGF-1 receptor
b-subunit, and antibody against tuberin were from Santa Cruz Technologies.364Antibody against a-tubulin was from Sigma. All other antibodies were from
Cell Signaling Technology.
The in vitro PI3K assay was carried out as described previously (Fruman
et al., 2000). Briefly, IRS-1 or IRS-2 immunoprecipitates from muscle lysates
was incubated with phosphatidylinositol (Avanti) and g-32P-ATP in kinase
buffer containing 20 mM Tris-HCl (pH 7.4), 100 mM NaCl, and 0.5 mM
EGTA. The lipid product was extracted in chloroform, separated by thin-layer
chromatography and quantified using a phosphorimager screen (Amersham
Biosciences).
For real-time RT-PCR quantification of muscle atrogin-1/MAFbx and
MuRF1 mRNA levels, mice were fasted for 36 hr (fast) and fed for 8 hr
(fed). Muscle total RNA was extracted using the RNeasy kit (Qiagen). The fol-
lowing primers were used for RT-PCR: atrogin-1/MAFbx forward 50-CTC TGT
ACC ATG CCG TTC CT-30, reverse 50-GGC TGC TGA ACA GAT TCT CC-30;
MuRF1 forward 50-ACG AGA AGA AGA GCG AGC TG-30, reverse 50-CTT
GGC ACT TGA GAG GAA GG-30; GAPDH forward 50-CGT CCC GTA GAC
AAA ATG GT-30, reverse 50-GAA TTT GCC GTG AGT GGA GT-30. Real-
time RT-PCR was carried using the SYBR green method (Applied Biosys-
tems). Atrogin-1/MAFbx and MuRF1 mRNA levels were normalized against
GAPDH mRNA.
Statistical analysis was carried out using Prism 4 (Graphpad Software) and
Microsoft Excel Statistics Toolkit (Microsoft). ANOVA and Student’s t tests
were applied. Results shown are mean6SEM, a p-value of <0.05 was con-
sidered to be statistically significant.
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